Avidity Partners Management
Latest statistics and disclosures from Avidity Partners Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are BSX, DNTH, ISRG, NTRA, CGON, and represent 18.69% of Avidity Partners Management's stock portfolio.
- Added to shares of these 10 stocks: UNH (+$51M), HUM (+$41M), CNTA (+$34M), KYMR (+$24M), BMRN (+$23M), Oruka Therapeutics (+$19M), TERN (+$18M), ASND (+$18M), BNTX (+$17M), EXAS (+$17M).
- Started 20 new stock positions in DYN, ZTS, PRLD, TERN, BMY, TMDX, Oruka Therapeutics, BMRN, UNH, QURE. ANRO, CNTA, Cybin, BNTX, ASND, KYMR, TIL, BLUE, ORIC, HUM.
- Reduced shares in these 10 stocks: CI (-$61M), , , AVTR (-$48M), ISRG (-$48M), , ARVN (-$37M), ABBV (-$35M), , GPCR (-$28M).
- Sold out of its positions in ABIO, SYRE, ALNY, AZN, CI, COLL, CRBP, CYBN, GILD, NTLA. IONS, JSPR, LNTH, LEGN, MRK, NUVB.WS, REGN, TYRA, PATH, UTHR, PCVX, ACIU, IMTX, WVE.
- Avidity Partners Management was a net seller of stock by $-573M.
- Avidity Partners Management has $2.0B in assets under management (AUM), dropping by -16.70%.
- Central Index Key (CIK): 0001791827
Tip: Access up to 7 years of quarterly data
Positions held by Avidity Partners Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Avidity Partners Management
Avidity Partners Management holds 81 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Boston Scientific Corporation (BSX) | 4.1 | $81M | -17% | 962k | 83.80 |
|
| Dianthus Therapeutics (DNTH) | 4.1 | $80M | 2.9M | 27.38 |
|
|
| Intuitive Surgical Com New (ISRG) | 3.7 | $73M | -39% | 148k | 491.27 |
|
| Natera (NTRA) | 3.6 | $71M | -27% | 556k | 126.95 |
|
| Cg Oncology (CGON) | 3.2 | $63M | +27% | 1.7M | 37.73 |
|
| Acadia Healthcare (ACHC) | 3.2 | $63M | -12% | 985k | 63.41 |
|
| Neurocrine Biosciences (NBIX) | 2.7 | $53M | -6% | 460k | 115.22 |
|
| UnitedHealth (UNH) | 2.6 | $51M | NEW | 87k | 584.68 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 2.4 | $48M | -20% | 431k | 111.41 |
|
| Syndax Pharmaceuticals (SNDX) | 2.4 | $47M | -26% | 2.5M | 19.25 |
|
| Perspective Therapeutics Com New (CATX) | 2.3 | $46M | +13% | 3.4M | 13.35 |
|
| Glaukos (GKOS) | 2.3 | $45M | +53% | 345k | 130.28 |
|
| Ideaya Biosciences (IDYA) | 2.2 | $44M | +22% | 1.4M | 31.68 |
|
| Insmed Com Par $.01 (INSM) | 2.2 | $43M | +37% | 592k | 73.00 |
|
| Thermo Fisher Scientific (TMO) | 2.2 | $42M | -14% | 69k | 618.57 |
|
| Tenet Healthcare Corp Com New (THC) | 2.1 | $42M | -31% | 253k | 166.20 |
|
| Ultragenyx Pharmaceutical (RARE) | 2.1 | $42M | -21% | 752k | 55.55 |
|
| Humana (HUM) | 2.1 | $41M | NEW | 130k | 316.74 |
|
| EXACT Sciences Corporation (EXAS) | 2.0 | $40M | +73% | 588k | 68.12 |
|
| Illumina (ILMN) | 1.9 | $38M | -38% | 292k | 130.41 |
|
| Arvinas Ord (ARVN) | 1.9 | $37M | -49% | 1.5M | 24.63 |
|
| Revolution Medicines (RVMD) | 1.8 | $36M | +4% | 790k | 45.35 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 1.7 | $34M | NEW | 2.1M | 15.99 |
|
| Phathom Pharmaceuticals (PHAT) | 1.7 | $33M | +11% | 1.8M | 18.08 |
|
| Xenon Pharmaceuticals (XENE) | 1.6 | $32M | +8% | 818k | 39.37 |
|
| Avantor (AVTR) | 1.6 | $32M | -59% | 1.2M | 25.87 |
|
| Blueprint Medicines (BPMC) | 1.5 | $29M | -17% | 315k | 92.50 |
|
| Mirum Pharmaceuticals (MIRM) | 1.5 | $29M | 731k | 39.00 |
|
|
| Surgery Partners (SGRY) | 1.4 | $27M | -36% | 827k | 32.24 |
|
| Axsome Therapeutics (AXSM) | 1.4 | $27M | -21% | 296k | 89.87 |
|
| Danaher Corporation (DHR) | 1.3 | $26M | -36% | 95k | 278.02 |
|
| Janux Therapeutics (JANX) | 1.3 | $26M | -33% | 562k | 45.43 |
|
| Neumora Therapeutics (NMRA) | 1.2 | $24M | 1.8M | 13.21 |
|
|
| Kymera Therapeutics (KYMR) | 1.2 | $24M | NEW | 500k | 47.33 |
|
| Biohaven (BHVN) | 1.2 | $23M | +3% | 465k | 49.97 |
|
| BioMarin Pharmaceutical (BMRN) | 1.1 | $23M | NEW | 320k | 70.29 |
|
| Argenx Se Sponsored Adr (ARGX) | 1.1 | $21M | -36% | 38k | 542.08 |
|
| Incyte Corporation (INCY) | 1.0 | $20M | -41% | 308k | 66.10 |
|
| Abbvie (ABBV) | 1.0 | $20M | -64% | 100k | 197.48 |
|
| Oruka Therapeutics | 1.0 | $19M | NEW | 791k | 24.51 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 1.0 | $19M | -59% | 431k | 43.89 |
|
| Neurogene (NGNE) | 0.9 | $18M | -41% | 425k | 41.96 |
|
| Terns Pharmaceuticals (TERN) | 0.9 | $18M | NEW | 2.1M | 8.34 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.9 | $18M | NEW | 119k | 149.31 |
|
| Biontech Se Sponsored Ads (BNTX) | 0.9 | $17M | NEW | 145k | 118.77 |
|
| Intra Cellular Therapies (ITCI) | 0.9 | $17M | -41% | 233k | 73.17 |
|
| Keros Therapeutics (KROS) | 0.9 | $17M | -14% | 293k | 58.07 |
|
| Dex (DXCM) | 0.8 | $16M | -7% | 240k | 67.04 |
|
| Oric Pharmaceuticals (ORIC) | 0.8 | $15M | NEW | 1.4M | 10.25 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.8 | $15M | +59% | 890k | 16.60 |
|
| Context Therapeutics (CNTX) | 0.7 | $15M | 7.4M | 1.96 |
|
|
| Zoetis Cl A (ZTS) | 0.7 | $14M | NEW | 71k | 195.38 |
|
| Rocket Pharmaceuticals (RCKT) | 0.7 | $14M | -31% | 749k | 18.47 |
|
| Immunic (IMUX) | 0.7 | $14M | -7% | 8.3M | 1.65 |
|
| Bristol Myers Squibb (BMY) | 0.7 | $14M | NEW | 263k | 51.74 |
|
| Immunome (IMNM) | 0.7 | $13M | 874k | 14.62 |
|
|
| Regenxbio Inc equity us cm (RGNX) | 0.6 | $12M | -12% | 1.1M | 10.49 |
|
| Cogent Biosciences (COGT) | 0.6 | $11M | 1.0M | 10.80 |
|
|
| Apogee Therapeutics (APGE) | 0.5 | $9.0M | -68% | 154k | 58.74 |
|
| Privia Health Group (PRVA) | 0.4 | $8.5M | -38% | 467k | 18.21 |
|
| Cybin Com New | 0.4 | $8.2M | NEW | 918k | 8.89 |
|
| Establishment Labs Holdings Ord (ESTA) | 0.4 | $7.3M | -68% | 169k | 43.27 |
|
| Cullinan Oncology (CGEM) | 0.4 | $7.1M | -72% | 425k | 16.74 |
|
| Immunocore Hldgs Ads (IMCR) | 0.3 | $6.2M | 200k | 31.13 |
|
|
| Dyne Therapeutics (DYN) | 0.3 | $5.9M | NEW | 165k | 35.92 |
|
| Sanofi Sponsored Adr (SNY) | 0.3 | $5.8M | -68% | 100k | 57.63 |
|
| Editas Medicine (EDIT) | 0.3 | $5.0M | +79% | 1.5M | 3.41 |
|
| Transmedics Group (TMDX) | 0.2 | $4.3M | NEW | 28k | 157.00 |
|
| Kezar Life Sciences (KZR) | 0.2 | $3.9M | 5.0M | 0.77 |
|
|
| Uniqure Nv SHS (QURE) | 0.2 | $3.3M | NEW | 674k | 4.93 |
|
| Immunovant (IMVT) | 0.1 | $2.8M | -89% | 99k | 28.51 |
|
| Alto Neuroscience Com Shs (ANRO) | 0.1 | $2.7M | NEW | 240k | 11.44 |
|
| Prime Medicine (PRME) | 0.1 | $2.7M | 694k | 3.87 |
|
|
| Syros Pharmaceuticals Com New (SYRS) | 0.1 | $2.3M | -36% | 1.1M | 2.15 |
|
| Scynexis Com New (SCYX) | 0.1 | $2.2M | 1.4M | 1.49 |
|
|
| Instil Bio Com New (TIL) | 0.1 | $2.0M | NEW | 29k | 67.32 |
|
| Prelude Therapeutics (PRLD) | 0.1 | $1.8M | NEW | 890k | 2.07 |
|
| Karyopharm Therapeutics (KPTI) | 0.1 | $1.7M | 2.0M | 0.83 |
|
|
| Hyperfine Com Cl A (HYPR) | 0.1 | $1.3M | 1.2M | 1.08 |
|
|
| Bluebird Bio (BLUE) | 0.0 | $847k | NEW | 1.6M | 0.52 |
|
| Caremax Cl A New (CMAX) | 0.0 | $36k | 21k | 1.70 |
|
Past Filings by Avidity Partners Management
SEC 13F filings are viewable for Avidity Partners Management going back to 2019
- Avidity Partners Management 2024 Q3 filed Nov. 14, 2024
- Avidity Partners Management 2024 Q2 filed Aug. 14, 2024
- Avidity Partners Management 2024 Q1 filed May 15, 2024
- Avidity Partners Management 2023 Q4 filed Feb. 14, 2024
- Avidity Partners Management 2023 Q3 filed Nov. 14, 2023
- Avidity Partners Management 2023 Q2 filed Aug. 14, 2023
- Avidity Partners Management 2023 Q1 filed May 15, 2023
- Avidity Partners Management 2022 Q4 filed Feb. 14, 2023
- Avidity Partners Management 2022 Q3 filed Nov. 14, 2022
- Avidity Partners Management 2022 Q2 filed Aug. 15, 2022
- Avidity Partners Management 2022 Q1 filed May 16, 2022
- Avidity Partners Management 2021 Q4 filed Feb. 14, 2022
- Avidity Partners Management 2021 Q3 filed Nov. 15, 2021
- Avidity Partners Management 2021 Q2 filed Aug. 16, 2021
- Avidity Partners Management 2021 Q1 filed May 17, 2021
- Avidity Partners Management 2020 Q4 filed Feb. 16, 2021